Scientific Industries (SCND) AI Stock Analysis

15 Followers

Top Page

Scientific Industries

(OTC:SCND)

48Neutral

The overall score reflects significant financial and operational challenges facing Scientific Industries, including declining revenue and profitability issues. While there is positive momentum from strategic transformations and growth in key business segments, particularly in the U.S., the company faces valuation concerns and bearish technical indicators.

Scientific Industries (SCND) vs. S&P 500 (SPY)

Market Cap

$9.66M

Dividend YieldN/A

Average Volume (3M)2.74K

Price to Earnings (P/E)―

Beta (1Y)0.44

Revenue Growth-1.68%

EPS Growth46.14%

CountryUS

Employees63

SectorTechnology

Sector Strength40

IndustryHardware, Equipment & Parts

Share Statistics

EPS (TTM)-0.61

Shares Outstanding10,503,599

10 Day Avg. Volume1,556

30 Day Avg. Volume2,743

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)1.44

Price to Cash Flow (P/CF)-3.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Scientific Industries Business Overview & Revenue Model

Company DescriptionScientific Industries (SCND) is a leading innovator in the design and production of benchtop laboratory equipment and related products for the scientific research and industrial markets. The company primarily operates in the biotechnology, pharmaceutical, and industrial sectors, providing products such as vortex mixers, shakers, incubators, and bioprocessing systems. These tools are essential for laboratories and research facilities to conduct experiments and develop new products efficiently and effectively.

How the Company Makes MoneyScientific Industries generates revenue through the manufacturing and sale of its laboratory equipment and related products. The company's primary revenue streams include direct sales to research institutions, universities, and industrial laboratories, as well as through distributors and online sales channels. Additionally, SCND may engage in strategic partnerships with biotech and pharmaceutical companies to develop specialized equipment, which can lead to exclusive contracts and recurring revenues. The company's focus on innovation and quality ensures a steady demand for its products, contributing to its financial success.

Scientific Industries Financial Statement Overview

Summary

Scientific Industries is facing profitability and cash flow challenges, with declining revenue growth and significant losses impacting margins. Despite a strong equity position and low leverage, the company's operational struggles and liquidity issues pose risks to financial stability.

Income Statement

Negative

Scientific Industries shows declining revenue growth with a drop in annual revenue from $10,475,600 to $11,111,500, resulting in negative revenue growth. The company has a negative net profit margin and EBIT margin due to significant losses in 2023, indicating profitability challenges. Despite a moderate gross profit margin, overall profitability remains weak.

Balance Sheet

Neutral

The company maintains a strong equity position with a high equity ratio, indicating financial stability. However, the negative net income impacts return on equity. The debt-to-equity ratio remains low, showing minimal leverage, which is a positive aspect of the balance sheet.

Cash Flow

Negative

The company faces negative free cash flow growth and significant operating cash flow deficits. The operating cash flow to net income ratio indicates cash flow challenges relative to reported losses, highlighting liquidity issues.

Dec 2023	Dec 2022	Jun 2022	Jun 2021	Jun 2020
Breakdown
Income Statement		Total Revenue
11.11M	10.48M	9.78M	8.57M	10.20M
	Gross Profit
5.10M	4.64M	4.98M	3.85M	4.37M
	EBIT
-9.26M	-8.17M	-4.71M	-1.14M	776.10K
	EBITDA
-8.51M	-7.41M	-4.46M	-979.00K	1.03M
	Net Income Common Stockholders
-9.09M	-8.15M	-3.11M	-703.30K	645.60K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.72M	6.20M	13.42M	7.89M	1.93M
	Total Assets
16.73M	18.07M	29.01M	14.80M	8.28M
	Total Debt
1.33M	0.00	1.49M	1.47M	140.00K
	Net Debt
535.80K	-1.93M	-8.19M	-6.09M	-1.46M
	Total Liabilities
2.85M	3.28M	2.78M	3.08M	1.94M
	Stockholders Equity
13.89M	14.79M	26.22M	11.72M	6.34M
Cash Flow		Free Cash Flow
-6.29M	-6.20M	-3.56M	-244.80K	947.10K
	Operating Cash Flow
-6.16M	-5.70M	-3.30M	-168.10K	1.16M
	Investing Cash Flow
-735.10K	3.61M	-10.88M	-84.10K	-218.40K
	Financing Cash Flow
5.75M	2.31M	16.31M	6.21M	-391.70K

Scientific Industries Technical Analysis

Technical Analysis Sentiment

Negative

Last Price0.85

Price Trends

50DMA

1.04

Negative

100DMA

1.01

Negative

200DMA

1.18

Negative

Market Momentum

MACD

-0.02

Positive

RSI

49.20

Neutral

STOCH

34.09

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.04, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 49.20 is Neutral, neither overbought nor oversold. The STOCH value of 34.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCND.

Scientific Industries Risk Analysis

Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Scientific Industries Peers Comparison

Overall Rating

UnderperformOutperform

Sector (57)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MTD	72 Outperform	$21.31B	25.47	-680.23%	―	2.22%	12.78%
TMO	70 Outperform	$165.21B	26.48	13.15%	0.36%	0.05%	6.87%
A	68 Neutral	$29.37B	23.67	20.61%	0.93%	-3.00%	3.67%
Sector *	57 Neutral	$18.52B	9.81	-13.96%	2.71%	5.07%	-23.65%
BIO	49 Neutral	$6.33B	―	-24.09%	―	-3.92%	-202.80%
ILMN	49 Neutral	$11.75B	―	-30.11%	―	-2.93%	-4.69%
SCND	48 Neutral	$9.66M	―	-56.04%	―	-1.68%	46.14%

* Technology Sector Average

Performance Comparison

SCND

Scientific Industries

0.85

-0.87

-50.58%

Agilent

103.59

-39.80

-27.76%

BIO

Bio-Rad Laboratories

229.40

-96.92

-29.70%

ILMN

Illumina

73.45

-53.01

-41.92%

MTD

Mettler-Toledo

1,032.15

-272.12

-20.86%

TMO

Thermo Fisher

437.87

-139.25

-24.13%

Scientific Industries Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: -13.27% | Next Earnings Date: May 14, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.

Highlights

VIVID Pill Counter Business Growth

VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.

Cost-Cutting Initiatives

The company successfully reduced operating expenses by over $1 million, or roughly 22%, compared to the same time frame last year, and improved cash burn rate without affecting the top line.

Bioprocessing Segment Performance

Sales compared to last year were up 12%, with improved gross margins and lower expenditures, resulting in a 27% improvement in EBITDA. The U.S. team reported a breakeven result with a positive EBITDA margin of 14%.

Strong Pipeline and New Product Development

A 90% increase in the commercial pipeline value was reported, alongside significant advancements in key projects such as the development of PAH technology and the new generation of the liquid injection system.

Strategic Partnerships

Secured partnerships and endorsements from major industry players like Merck, which are expected to positively influence the company's commercial track.

Lowlights

Challenging Bioprocessing Market

The bioprocessing segment faced a challenging environment with budget constraints impacting customers, particularly in Europe, leading to postponed equipment investments.

Company Guidance

During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.